(USD) | Jun 2024 | Q/Q |
---|---|---|
Revenue | 10.4B | +4% |
Gross Profit | 5.8B | - |
Cost Of Revenue | 4.6B | +3% |
Operating Income | 1.7B | +20% |
Operating Expenses | 4.1B | - |
Net Income | 1.3B | +6% |
R&D | 698MM | +2% |
G&A | 2.9B | -1% |
Amortization | 471MM | -0% |
Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Abbott (NYSE: ABT) today announced that the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms,1 has been implanted for the first time at the Montreal Heart Institute, in Montreal, Quebec and Foothills Medical Centre in Calgary, Alberta.
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Abbott Laboratories (NYSE:ABT), which manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs, is set to report its Q3 2024 earnings on ...
This is what could happen next to AbbVie shares.
We recently compiled a list of 10 Best Dividend Aristocrats According to Wall Street Analysts. In this article we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other dividend aristocrats. Shifts in investment trends have revealed new insights for investors in recent years. Certain times call for specific investments, and […]
Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.
Rapid Covid-19 Testing with Abbott ID Now Abbott Laboratories (Abbott), a world-leading medical devices and healthcare company, is one of the leaders in Covid-19 testing with its three diagnostic PCR tests: the ID NOW, m2000, and Alinity m. Abbott has shipped nearly 4.5 million of its point-of-care (POC) ID NOW tests, and nearly 4 million…
An unexpected diabetes partnership with Medtronic bodes well for Abbott's biggest growth driver.
You aren't powerless in the face of what the market throws at you.
Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.